BTIG lowered the firm’s price target on BioAtla (BCAB) to $10 from $13 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s December equity raise, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress
- BioAtla announces restructuring, to cut over 30% of workforce
- BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year
- BCAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioAtla Awards Executive Bonuses and Stock Units